Compounds The DrugMatrix system is built on a foundation of the existing pharmacopoeia of active drug ingredients and select chemical standards in the pharmaceutical industry. To date, over 800 compounds have been profiled in molecular pharmacology assays, and of these, over 550 have been studied in gene expression microarray experiments — many of these in multiple tissues. DrugMatrix focuses on a diverse set of compounds, including the following:

• Approved Drugs from the U.S. The “formulary” of all active ingredients, including such examples as steroids, beta agents, statins, anti-neoplastics, anti-infectives, and other categories that completely include the major elements of drug therapy today.
  
• Non-U.S. Approved Drugs and Close Relatives. Expands the library to include other molecules with extensive in vivo and clinical experience.
  
• Withdrawn Drugs. Includes such recent high-profile failures as Baycol and other compounds that have failed in late-stage clinical trials or post approval.
  
• Standard Toxicants. Compounds considered to be standards by most toxicologists, including known carcinogens, known liver toxicants, and other toxicology benchmarks.
  
• Standard Biochemicals. Compounds used in well established biochemical assays to characterize the activity of defined sets of protein targets and that validate well established biochemical assays.